Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Receives Average Recommendation of "Moderate Buy" from Brokerages

Shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Get Free Report) have earned a consensus rating of "Moderate Buy" from the six analysts that are presently covering the company, MarketBeat reports. Two investment analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $5.17.

Several research firms recently weighed in on SGMO. Royal Bank of Canada restated a "sector perform" rating and issued a $2.00 price objective on shares of Sangamo Therapeutics in a research report on Tuesday, March 18th. Truist Financial lowered their price objective on shares of Sangamo Therapeutics from $7.00 to $5.00 and set a "buy" rating for the company in a research report on Thursday, January 23rd. Finally, HC Wainwright reaffirmed a "buy" rating and set a $10.00 price target on shares of Sangamo Therapeutics in a research report on Monday, April 7th.

Sangamo Therapeutics Trading Down 1.7 %

NASDAQ SGMO opened at $0.73 on Monday. Sangamo Therapeutics has a 1 year low of $0.30 and a 1 year high of $3.18. The company has a market cap of $166.92 million, a P/E ratio of -0.97 and a beta of 1.46. The company has a fifty day simple moving average of $0.81 and a 200 day simple moving average of $1.38.

Sangamo Therapeutics (NASDAQ:SGMO - Get Free Report) last posted its quarterly earnings results on Monday, March 17th. The biopharmaceutical company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.09) by ($0.02). The firm had revenue of $7.55 million during the quarter, compared to analyst estimates of $11.70 million. Sangamo Therapeutics had a negative net margin of 257.87% and a negative return on equity of 264.16%. Equities research analysts forecast that Sangamo Therapeutics will post -0.46 EPS for the current fiscal year.

Institutional Trading of Sangamo Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of SGMO. SBI Securities Co. Ltd. purchased a new position in shares of Sangamo Therapeutics in the 4th quarter worth about $28,000. Geode Capital Management LLC grew its position in shares of Sangamo Therapeutics by 14.6% during the 3rd quarter. Geode Capital Management LLC now owns 2,138,309 shares of the biopharmaceutical company's stock valued at $1,853,000 after acquiring an additional 272,123 shares during the period. Golden State Equity Partners raised its holdings in shares of Sangamo Therapeutics by 2,592.3% in the 4th quarter. Golden State Equity Partners now owns 325,684 shares of the biopharmaceutical company's stock worth $332,000 after purchasing an additional 313,587 shares during the period. Charles Schwab Investment Management Inc. lifted its stake in Sangamo Therapeutics by 3.3% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,139,252 shares of the biopharmaceutical company's stock valued at $1,162,000 after purchasing an additional 35,926 shares during the last quarter. Finally, PNC Financial Services Group Inc. grew its holdings in Sangamo Therapeutics by 2,319.1% during the fourth quarter. PNC Financial Services Group Inc. now owns 26,078 shares of the biopharmaceutical company's stock valued at $27,000 after purchasing an additional 25,000 shares during the period. 56.93% of the stock is owned by hedge funds and other institutional investors.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.